CG Bio exports fillers to the Middle East, Sweden
CG Bio said it has signed a contract to export 5.7 billion won ($ 4.4 million) of Facetem S and AiLEENE, its complementary products, to the Middle East and Sweden.
The company will export its 4.9 billion won fillers to seven countries in the Middle East, including Syria and the Gulf Cooperation Organization (GCC) member countries in Saudi Arabia and the United Arab Emirates, and 800 million won to Sweden.
CG Bio said that they could complete the agreement with Sweden at the recently concluded International Aesthetic Plastic Surgery Society (IMCAS) 2022 in Paris on 3-5 June. CG Bio had run a PR stand at the congress and actively promoted the excellence of top products and was able to hold business meetings with about 150 companies.
“IMCAS 2022 was an event to promote the excellent technology of CG Bio Filler products and gain a sense of interest from buyers around the world,” said CG Bio CEO Yu Hyun-seung. “We will continue to expand the global market by discovering new buyers by developing innovative medical technology products and participating in foreign conferences.”
Facetem S is a calcium filler manufactured with a lattice-pore structure, in which particles of high purity 99.49 percent hydroxyapatite (HA) processed with CG Bio’s manufacturing technology are stacked with hard shells. The hallmark of the filler includes preventing sudden volume decrease and enhancing the feeling of injection with uniform particles.
The company exports Facetem S after obtaining local licenses in eight countries, including Russia and Spain.
AiLEENE is a hyaluronic acid filler that applies the world’s first two-in-one multilayer method that mixes crosslinked gel and crosslinked particles with a patented method and then applies a rotational process. The filler also improves safety by minimizing the modification of the degree value. But according to CG Bio, this factor can cause side effects such as edema and inflammation while filling well with high volume and cohesion.